Sinomenine suppresses expression of interleukin- 1beta-induced matrix metalloproteinases in human osteoarthritic chondrocytes

Journal of Medicinal Plants Research

Volumn 4, Issue 18, 2010, Pages 1830-1836

  Huang, Bao Ding ^a   He, Ai Shan ^a   Fu, Ming ^a   Sheng, Puyi ^a   Liao, Wei Ming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chondrocytes; Interleukin 1; Matrix metalloproteinases; Osteoarthritis; Sinomenine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COLLAGENASE 3; GELATINASE B; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; RECOMBINANT PROTEIN; SINOMENINE; STROMELYSIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CATABOLISM; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME REPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KNEE OSTEOARTHRITIS; MONOLAYER CULTURE; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING;

SINOMENIUM ACUTUM;

EID: 78549266121     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abramson SB, Yazici Y (2006). Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Advanced. Drug. Deliv. Rev., 58(2): 212-225.
2. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M (1986). Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis. Rheum., 29: 1039-1049.
3. Andreas K, Häupl T, Lübke C, Ringe J, Morawietz L, Wachtel A, Sittinger M, Kaps C (2009). Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis. Res. Ther., 11: 15.
4. Attur MG, Dave M, Akamatsu M, Katoh M, Amin AR (2002). Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine. Osteoarthritis Cartilage, 10: 1-4.
5. Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, Abramson SB, Amin AR (2000). Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J. Biol. Chem., 275: 40307-4315.
6. Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, Rhee HI, Ryu KH, Jung K, Han CK, Kwak WJ, Cho YB (2002). Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage. 10: 471-478.
7. Clark IM, Parker AE (2003). Metalloproteinases their role in arthritis and potential as therapeutic targets. Expert. Opin. Ther. Targets., 7: 19-34.
8. Dickinson SC, Vankemmelbeke MN, Buttle DJ, Rosenberg K, Heinegard D, Hollander AP (2003). Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix. Biol., 22: 267-278.
9. Feng H, Yamaki K, Takano H, Inoue K, Yanagisawa R, Yoshino S (2007). Effect of sinomenine on collagen-induced arthritis in mice. Autoimmunity. 40: 532-539.
10. Jenkins JK, Seligman PJ (2005). Memorandum: Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk. US FDA. April 6. Available from: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf
11. Ke XY, Xiu MX (1986). Treatment of rheumatoid arthritis by sinomenine. Beijing Yixue. 3: 186-187.
12. Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, Feige U, Poole AR (2005). Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis. Rheum., 52: 128-135.
13. Kok TW, Yue PY, Mak NK, Fan TP, Liu L, Wong RN (2005). The antiangiogenic effect of sinomenine. Angiogenesis. 8: 3-12.
14. Kondo Y, Takano F, Yoshida K, Hojo H (1994). Protection by sinomenine against endotoxin-induced fulminant hepatitis in galactosaminesensitized mice. Biochem. Pharmacol., 48: 1050-1052.
15. Li XJ, Yue PY, Ha WY, Wong DY, Tin MM, Wang PX, Wong RN, Liu L (2006). Effect of sinomenine on gene expression of the IL-1 betaactivated human synovial sarcoma. Life. Sci., 79: 665-673.
16. Liacini A, Sylvester J, Zafarullah M (2003). Triptolide suppresses proinflammatory cytokine-induced matrix metalloproteinase and aggrecanase-1 gene expression in chondrocytes. Biochem Biophys Res Commun., 327: 320-327.
17. Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B (1999). Aggrecanase versus matrix m etalloproteinases in t he catabolism of the interglobular domain of aggrecan in vitro. Biochem. J., 344: 61-68.
18. Liu L, Riese J, Resch K, Kaever V (1994). Impairment of macrophage eicosanoid and nitric oxide production by an alkaloid from Sinomenium acutum. Arzneimittelforschung. 44: 1223-1226.
19. Liu L, Buchner E, Beitze D, Schmidt-Weber CB, Kaever V, Emmrich F, Kinne RW (1996a). Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Int. J. Immunopharmacol., 18: 529-543.
20. Liu L, Resch K, Kaever V (1996b). Inhibition of lymphocyte proliferation by the anti-arthritic drug sinomenine. Int. J. Immunopharmacol., 16: 685-691.
21. Pelletier JP, Martel-Pelletier J, Raynauld JP (2006). Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis. Res. Ther., 8: 206.
22. Pelletier JP, Martel-Pelletier J (2007). DMOAD developments: present and future. Bulletin of the NYU hospital for joint diseases. 65(3): 242-248.
23. Pérez P, Kwon YJ, Alliende C, Leyton L, Aguilera S, Molina C, Labra C, Julio M, Leyton C, González MJ (2005). Increased acinar damage of salivary glands of patients with Sjogren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios. Arthritis. Rheum., 52: 2751-2760.
24. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort JG (2004). Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann. Rheum. Dis., 63: 931-939.
25. Qian L, Xu Z, Zhang W, Wilson B, Hong JS, Flood PM (2007). Sinomenine, a natural dextrorotatory morphinan analog, is antiinflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J. Neuroinflammation., 4: 23.
26. Rannou F, Francois M, Corvol MT, Berenbaum F (2006). Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine. 73: 29-36.
27. Steinmeyer J, Konttinen YT (2006). Oral treatment options for degenerative joint disease--presence and future. Adv. Drug. Deliv. Rev., 58: 168-211.
28. Song YW, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Baek HJ, Kim HA, Suh YI, Kang SW, Lee YJ, Jung HG (2007). Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. Clin Ther., 29: 862-873.
29. Vieregge B, Resch K, Kaever V (1999). Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. Planta. Med., 65: 80-82.
30. Vincenti MP, Brinckerhoff CE (2001). Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin- 1beta. Arthritis. Res., 3: 381-388.
31. Wang Y, Fang Y, Huang W, Zhou X, Wang M, Zhong B, Peng D (2005). Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethnopharmacol., 98: 37-43.
32. Wu W, Billinghurst RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, Poole AR (2002). Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum. 46: 2087-94.
33. Yamasaki H (1976). Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta. Med. Okayama., 30: 1-20.